🚨Trade Alert 🚨 PHIO

The biotech space ended on a very BULLIsh note last week and this underfollowed biotech company may be the next to see blue-sky growth. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Greetings All, As 2023 inches closer to an end, there are still a few weeks to go to uncover phenomenal and promising companies to keep your eyes on this year and beyond. The biotech arena had an exciting finish in the last week after Big Pharma’s $10.1 billion deal splash. Stocks in the space saw a lift on the news that AbbVie [announced plans to buy cancer developer ImmunoGen]( for $31.26 a share. This marks about a 95% premium to Immunogen’s closing price last Wednesday! With momentum going, now is the time to have underfollowed biotech company Phio Pharmaceuticals Corp. on your radar. The NASDAQ-traded stock trades under the ticker symbol “PHIO.” PHIO is a clinical-stage biotech co-founded by the Nobel scientist who discovered RNA interference. The stock is currently trading a little over $1 and carries a “STRONG BUY” rating at [NASDAQ.com.]( In an August report, [Vernon Bernardino]( from H.C. Wainwright reiterated a “BUY” rating on Phio Pharmaceuticals ([PHIO – Research Report]( with a price target of $6.00. According to [TipRanks]( Bernardino is a 4-star analyst with an average return of 10.0%. A $6 price target indicates a potential upside of 400%! And this is just one reason to have PHIO on your radar! Who is Phio Pharmaceuticals Corp.? PHIO is a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells. What is Intasyl? INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs are designed to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. INTASYL is a patented precision delivery technology that delivers uniquely designed gene-silencing compounds to any gene target in the human genome. It effectively targets messenger RNA to suppress specific proteins, genetically encoded in the DNA, that can interfere with the body’s immune cells in killing cancer cells, resulting in the reduction of specific protein targets. It has been safely tested in human trials in >170 patients. The INTASYL technology facilitates the creation of unique, chemically modified siRNA compounds (INTASYL compounds), which can be delivered to a broad range of cell types and tissues without the need for enhancements. INTASYL’s innovative approach features a simplified chemical composition, effectively reducing toxicity and enhancing tolerability and efficacy. This technology is adaptable to both intra-tumoral and adoptive cell therapy (ACT) applications, ensuring a versatile and potent therapeutic platform for gene silencing. See how it works in this video HERE: [How INTASYL Helps the Body's Defenses Overcome Cancer in Ways Others Cannot]( Key Clinical Initiatives & Programs: PH-762 The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762. [Learn more about the clinical trial.]( PH-894 PH-894 is designed to silence the BRD4 protein. Overexpression of BRD4 is often associated with cancer progression, invasion, and metastasis. What sets PH-894’s approach to silencing BRD4 apart is its dual activity in suppressing BRD4 in both T cells and in tumor cells: PH-894’s suppression of BRD4 in T cells results in T cell activation; additionally, suppression of BRD4 in tumor cells results in tumors becoming more sensitive to T-cell killing. [Learn more]( A Big Development on PH-762: PH-762, the company’s lead pipeline product, has received an investigational new drug (IND) application clearance from the FDA to initiate a clinical study on skin cancer indications. The FDA's clearance of the IND application for PH-762 marks a significant step toward the company's evolution from drug discovery to clinical development. And recently… the company enrolled the first patient in the company’s U.S. clinical trial with PH-762! “The initiation of enrollment in this trial represents a milestone as we develop PH-762 for the treatment of squamous cell and other skin cancers. We are optimistic that this novel, alternative immuno-oncology therapy may offer patients and their care providers, enhanced therapeutic outcomes while minimizing invasive intervention,” said President & CEO, Robert Bitterman. Favorable Data on Cancer Drug Candidate PH-894: Data from the first study showed that melanoma cells treated with PH-894 enhance their recognition of immune cells. This, in turn, increases their susceptibility to destruction by T cells. Based on this data, management concluded that PH-894 offers a strategy to reduce BRD4 expression (a protein associated with cancer growth) and simultaneously boost the immune response to cancer cells while minimizing the toxicities commonly associated with traditional systemic therapies. Data from another study demonstrated the effectiveness of PH-894 as an antitumor cytotoxic agent, i.e., directly killing tumor cells! This is based on in vitro tests conducted by management on multiple cancer cell lines (like breast cancer, lung cancer and ovarian cancer, among others) wherein treatment with PH-894 induces concentration-associated apoptosis (i.e., the process of programmed cell death). In summary… It’s hard to match the importance of the cancer realm in the biotech arena. Cancer is a disease that has even the biggest biotech companies scrambling to find treatments for. With two exciting candidates in its pipeline and studies underway, PHIO is a biotech company to keep your eyes closely on! Any encouraging data could be a catalyst for building shareholder value. Keep in mind that PHIO has a $6 price target! This is one biotech company to not dismiss as 2023 comes to an end. PHIO’s proprietary RNAi technology INTASYL™is designed to make immune cells more effective in killing tumor cells. 2024 could be a game-changing year for PHIO as it revolutionizes the way scientists think about precision medicine. Start your research! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in PHIO. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]